Vaccination Against SARS-Cov2 (COVID-19) in Chronic Inflammatory Rheumatism and Factors Determining Its Decision.

Vaccination Against SARS-Cov2 in Chronic Inflammatory Rheumatism and Factors Determining Its Decision.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04970550

Acronym

VACCI-RIC

Enrollment

150

Registered

2021-07-21

Start date

2021-06-01

Completion date

2021-11-30

Last updated

2022-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis, Spondyloarthritis

Keywords

SARS COV 2 vaccination

Brief summary

Rheumatoid arthritis and spondyloarthritis (ankylosing spondylitis and psoriatic arthritis mainly) are chronic inflammatory rheumatism (RIC), frequently onset in young adults. The prevalence is respectively 0.3 to 0.8% and 0.4%. or about 600,000 people. The basic treatments (DMARDs), essential to control the progression of the disease, are classified into csDMARDs (chemical), the first of which is methotrexate, or bDMARDs (biological). These treatments are immunomodulators and there is an increased risk of severe infection under these therapies. Several vaccinations are therefore recommended by learned societies in patients receiving these treatments, in order to prevent certain infectious risks.In the current pandemic context, the vaccination of these patients against SARS-Cov2 is a major issue in their management and is recommended by the French society of rheumatology. However, many patients express doubts about this vaccination or refuse it. The factors associated with the vaccination will are not known. Better identifying them would make it possible to adapt the information to be given to our patients to promote their adherence.

Interventions

OTHERNon intervention

Non intervention

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Ambulatory patients * Men or women of any age * Follow-ups for chronic inflammatory rheumatism such as rheumatoid arthritis or spondyloarthritis * Treated with methotrexate or biotherapy.

Exclusion criteria

* Patients not treated with biotherapy or methotrexate. * Patients in whom the assessment could not be performed reliably

Design outcomes

Primary

Measure	Time frame	Description
Determine the desire to be vaccinated against SARS-CoV2	At inclusion	Percentage of patients with RIC and treated with DMARDs who favor vaccination against SARS-CoV2 ; determined with a questionnaire

Secondary

Measure	Time frame	Description
Factors associated with the desire for vaccination against SARS-CoV2	At inclusion	Identify the factors associated with the desire for vaccination against SARS-CoV2 ; determined with a questionnaire

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026